An 18 Percent Solution? Lilly And Daiichi Bet On A Premium Price For Effient Over Plavix
This article was originally published in The Pink Sheet Daily
Executive Summary
Wall Street analysts fret over a black box warning and see a slow uptake for Effient, but still expect drug to reach blockbuster status.